Abstract:Exosomes (EXOs) derived from tumor cells have been used to stimulate antitumor immune responses. It has been demonstrated that EXO released by tumor cells engineered to express cytokines are of enhanced stimulatory effect on CD8(+) cytotoxic T-lymphocyte (CTL) responses and antitumor immunity. J558 is a mouse myeloma cell line expressing tumor antigen P1A. In this study, we purified EXOTNF-a, EXOIL-2, and EXOIFN-gamma released by three cytokine-gene (TNF-alpha, IL-2 and IFN-gamma)-engineered J558 (J558(TNF-a), J558(IL-2) and J558(IFN-gamma)) tumor cell lines from their culture supernatants, respectively, by differential ultracentrifugation. These EXOs showed a "saucer" or round shape with a diameter between 50 and 90 nm by electron microscopy and contained EXO-associated proteins, such as LAMP-1 and AIP1, but not lysate-associated protein galectin, by Western blot analysis. EXO displayed expression of molecules (H-2K(d), CD54, and P1A) similarly to, but to a lesser extent to, J558 tumor cells. We then compared the stimulatory effect of these EXOs on P1A-specific CD8(+) CTL responses and antitumor immunity 6 days subsequent to intravenous (i.v.) EXO immunization (30 mu g/each BALB/c mouse). We demonstrated that EXOTNF-alpha immunization was able to induce more efficient P1A-specific CD8(+) T-cell response accounting for 0.62% of the total CD8(+) T-cell population, using PE-H-2K(d)/P1A peptide and FITC-CD8 staining by flow cytometric analysis then EXOIL-2 (0.31%) and EXOIFN-gamma (0.22%) immunization (P < 0.05), respectively, at day 6 after immunization. EXOIL-2 and EXOIFN-gamma vaccine (i.v. 30 mu g/each mouse) only protected 3 of 8 (38%) and 2 of 8 (25%) mice from tumor growth after subcutaneous (s.c.) challenging of immunized mice with J558 tumor cells (0.5 x 10(6) cells/each mouse), whereas EXOTNF-alpha immunization protected all 8 of 8 (100%) mice from tumor growth (P < 0.05). Taken together, we demonstrate that EXOTNF-a released by engineered J558(TNF-a) tumor cells more efficiently stimulate tumor antigen P1A-specific CD8(+) CTL responses and antitumor immunity than EXOIL-2 and EXOIFN-gamma released by engineered J558(IL-2) and J558(IFN-gamma) tumor cells. Therefore, TNF-alpha-expressing tumor cell-released EXO may represent a more effective EXO-based vaccine in the induction of antitumor immunity.

Dendritic Cells Recruit T Cell Exosomes Via Exosomal LFA-1 Leading to Inhibition of CD8+ CTL Responses Through Downregulation of Peptide/MHC Class I and Fas Ligand-Mediated Cytotoxicity

CD4 + T cell-released exosomes inhibit CD8 + cytotoxic T-lymphocyte responses and antitumor immunity

Enhanced Suppression of Polyclonal CD8+25+ Regulatory T Cells Via Exosomal Arming of Antigen-Specific Peptide/mhc Complexes.

Natural Cd8(+)25(+) Regulatory T Cell-Secreted Exosomes Capable of Suppressing Cytotoxic T Lymphocyte-Mediated Immunity Against B16 Melanoma

Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.

Dendritic Cell-Derived Exosomes Stimulate Stronger Cd8(+) Ctl Responses and Antitumor Immunity Than Tumor Cell-Derived Exosomes

Novel Exosome-Targeted Cd4(+) T Cell Vaccine Counteracting Cd4(+)25(+) Regulatory T Cell-Mediated Immune Suppression and Stimulating Efficient Central Memory Cd8(+) Ctl Responses

Tumor Cell-Derived Exosome-Targeted Dendritic Cells Stimulate Stronger CD8+ CTL Responses and Antitumor Immunities

Redirecting Antigen Specificity to Nonspecific CD8+25+ Regular T Cells Through Antigen-Specific Peptide/mhc Complex Arming. (P1085)

Intestinal epithelial antigen induces mucosal CD8 T cell tolerance, activation, and inflammatory response.

Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity.

Orally Administered Exosomes Suppress Mouse Delayed-Type Hypersensitivity by Delivering miRNA-150 to Antigen-Primed Macrophage APC Targeted by Exosome-Surface Anti-Peptide Antibody Light Chains

Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumour immunity.

Increasing the Immune Activity of Exosomes: the Effect of Mirna-Depleted Exosome Proteins on Activating Dendritic Cell/cytokine-Induced Killer Cells Against Pancreatic Cancer.

Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8 + CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells

Exosomes with membrane-associated TGF-β1 from gene-modified dendritic cells inhibit murine EAE independently of MHC restriction.

CD4+ Th-APC with Acquired Peptide/mhc Class I and II Complexes Stimulate Type 1 Helper CD4+ and Central Memory CD8+ T Cell Responses.

The Anti-Tumor Activity of Dendritic Cell/cytotoxic T Lymphocyte Induced by Cholangiocarcinoma-Derived Exosome and Its Ultrafiltered Lysate

CD8+ T Activation Attenuates CD4+ T Proliferation Through Dendritic Cells Modification

CD4+ Th-APC with Acquired Peptide/MHC Class I and II Complexes Stimulate Type 1 Helper CD4+ and Central Memory CD8+ T Cell Responses1

Antigen Specificity Acquisition of Adoptive CD4+ Regulatory T Cells Via Acquired Peptide-MHC Class I Complexes1